Tim Kutzkey - 04 Apr 2024 Form 4 Insider Report for Surrozen, Inc./DE (SRZN)

Role
Director, 10%+ Owner
Signature
/s/James Evangelista, as attorney-in-fact for Tim Kutzkey
Issuer symbol
SRZN
Transactions as of
04 Apr 2024
Transactions value $
$2,999,994
Form type
4
Filing time
08 Apr 2024, 16:24:22 UTC
Previous filing
19 May 2023
Next filing
06 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRZN Common Stock Purchase $1,408,903 +90,897 +44.59% $15.5 294,767 04 Apr 2024 By The Column Group III, LP F1, F2
transaction SRZN Common Stock Purchase $1,591,090 +102,651 +44.59% $15.5 332,885 04 Apr 2024 By The Column Group III-A, LP F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRZN Series A Common Warrants Purchase +90,897 90,897 04 Apr 2024 Common Stock 90,897 $15.5 By The Column Group III, LP F1, F2, F4
transaction SRZN Series A Common Warrants Purchase +102,651 102,651 04 Apr 2024 Common Stock 102,651 $15.5 By The Column Group III-A, LP F1, F3, F4
transaction SRZN Series B Common Warrants Purchase +98,870 98,870 04 Apr 2024 Common Stock 98,870 $14.25 By The Column Group III, LP F1, F2, F5
transaction SRZN Series B Common Warrants Purchase +111,656 111,656 04 Apr 2024 Common Stock 111,656 $14.25 By The Column Group III-A, LP F1, F3, F5
transaction SRZN Series C Common Warrants Purchase +352,225 352,225 04 Apr 2024 Common Stock 352,225 $16 By The Column Group III, LP F1, F2, F6
transaction SRZN Series C Common Warrants Purchase +397,773 397,773 04 Apr 2024 Common Stock 397,773 $16 By The Column Group III-A, LP F1, F3, F6
transaction SRZN Series D Common Warrants Purchase +352,225 352,225 04 Apr 2024 Common Stock 352,225 $16 By The Column Group III, LP F1, F2, F7
transaction SRZN Series D Common Warrants Purchase +397,773 397,773 04 Apr 2024 Common Stock 397,773 $16 By The Column Group III-A, LP F1, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.
F2 The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F3 The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F4 These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.
F5 These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.
F6 These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).
F7 These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).